Context Therapeutics (CNTX) Liabilities and Shareholders Equity (2020 - 2026)

Context Therapeutics has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $58.9 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 36.69% year-over-year to $58.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $293.7 million (down 22.73% YoY) and the FY2025 annual result came in at $68.5 million, down 30.2% from the prior year.
• Liabilities and Shareholders Equity eased to $58.9 million in Q1 2026 per CNTX's latest filing, from $68.5 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $102.7 million in Q2 2024 and troughed at $11.1 million in Q1 2024.
• A 5-year average of $56.2 million and a median of $47.0 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity surged 1762.65% in 2022, then slumped 65.43% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $38.0 million in 2022, then tumbled by 57.69% to $16.1 million in 2023, then jumped by 510.9% to $98.1 million in 2024, then plunged by 30.2% to $68.5 million in 2025, then dropped by 14.07% to $58.9 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $58.9 million, $68.5 million, and $79.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.